ClinicalTrials.gg
RecruitingNCT07292298Updated Sep 2, 2026

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

A Phase 2 interventional study of High Rare Dose Rectal Brachytherapy Boost in Rectal Adenocarcinoma and Rectal Cancer, sponsored by University of Colorado, Denver. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 780 studies in Rectal Neoplasms with a site in United States — 81 open to participants now, 140 under way, 9 of them phase 3. Rectal Neoplasms · United States.

Planned enrollment
288th of 620
44 · median 39
Started
2026
with 18 others
Phase 2
232 of 780
21 open now
Primary completion
2030-11
later than 130 of 139 live
Registered
766th of 780
by date

Among the 780 studies in Rectal Neoplasms with a site in United States, this one is the 288th largest by planned enrollment of the 620 interventional ones that give a count, is one of 19 that started in 2026, is one of 232 in phase 2, reaches primary completion later than 130 of the 139 other live ones, and was the 766th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

81 of the 780 studies in Rectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

75 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 780 studies in Rectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation delivered internally (rectal brachytherapy) can provide complete responses and thus spare the requirement for surgery.

The main questions are whether: 1) rectal brachytherapy is safe in this clinical treatment paradigm and if 2) rectal brachytherapy improves organ preservation (no need for surgery).

The trial involves an additional MRI pelvis and sigmoidoscopy with marker placement to define high-risk residual disease for radiation planning. Subsequently, 3 outpatient brachytherapy treatments are given on a weekly basis. If a patient achieves a complete response to brachytherapy, standard of care non-operative surveillance visits are conducted with study visits aligned during the first two years following brachytherapy.

Read the detailed description

Rectal cancer patients with incomplete responses following standard of care chemotherapy and radiation are offered surgery as part of curative intent regimens. Similarly, patients with near-complete responses following initial therapy may require future salvage surgery given high local recurrence risk in the rectum. The goal of this study is to determine whether additional "internal" focal radiation delivered by rectal brachytherapy can provide a complete tumor response, such that patients can avoid surgical intervention. While rectal brachytherapy efficacy, technique, and safety has been demonstrated in previous studies conducted in Europe and Canada, it has not been tested to "boost" responses following standard of care chemotherapy/radiation in the United States.

Specifically, rectal brachytherapy treatment requires placement of a multichannel cylinder into the rectum following local analgesia and oral medication to improve procedure tolerability. A balloon on the cylinder is inflated to displace rectum uninvolved with tumor away from the internal high-dose radiation source that travels through the cylinder channels abutting the tumor. 21 Gy cumulative dose over 3 weekly treatments is administered to the high-risk rectal mucosa at a depth aligning to tumor thickness. The cylinder will be immobilized in the rectum for up to 3 hours during each of the 3 brachytherapy sessions, with radiation treatment being less than 10 minutes following completion of planning.

If complete response is achieved, surveillance visits will be conducted with an almost identical protocol to patients who achieve complete response following standard of care radiation/chemotherapy.

03

Conditions studied

  • Rectal Adenocarcinoma
  • Rectal Cancer

Browse trials for

Keywords

  • Locally Advanced Rectal Cancer
  • Non-metastatic Rectal Cancer
  • Rectal Neoplasms
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision to sign and date the consent form.
  2. Stated willingness to comply with all study procedures and be available for the duration of the study.
  3. Adults (18-100 years old)
  4. 0-3
  5. Patients with MMR-proficient low-mid rectal adenocarcinoma cT1-4 N0-2 M0 who underwent total therapy who have not achieved complete response (i.e. incomplete or near-complete) in the rectal primary tumor such that surgical resection, if offered presently or in the future, would be an APR or low LAR per colorectal surgeon expert opinion and central review at University of Colorado rectal tumor board. Tumor restaging will be 4-16 weeks following completion of total neoadjuvant therapy, and no sooner than 8 weeks if patients received chemotherapy followed by chemoradiation/short course radiation.
  6. Residual rectal disease must have its craniocaudal extent \<4 cm with thickness \<1.2 cm. Tumor must have \<50% circumferential involvement. Residual disease must be above the dentate line and not involving the anal canal.
  7. In patients with original cN1-2 disease, restaging CT and MRI after total neoadjuvant therapy must demonstrate at least near-complete response of the pelvic lymph nodes per NCCN criteria as evaluated by central review at University of Colorado rectal tumor board.
  8. Interval of time between completion of TNT and initiation of rectal brachytherapy must be between 4-16 weeks.
  9. Patients must be recovered from total neoadjuvant therapy and must not have significant rectal incontinence at time of screening.
  10. Received conventionally fractionated external beam chemoradiation between 45-56 Gy or short-course external beam radiation prescription of 25 Gy to rectal mucosa, in addition to systemic chemotherapy before or after radiation per National Comprehensive Cancer Network (NCCN) guidelines.
  11. Women of must have a negative urine or serum pregnancy test within 14 days of HDR treatment.
  12. Men and women of who are sexually active must agree to follow instructions of for the duration of the study and 6 months post-rectal brachytherapy completion.
  13. CBC at the time of screening must have >50 10\^9/L, >8 g/dL and > 500 10\^9/L

Exclusion criteria

Exclusion Criteria:

  1. History of ulcerative colitis or Crohn's disease.
  2. Pelvic radiotherapy given prior to rectal cancer external beam radiation.
  3. Prior colorectal surgery in which anastomotic site is at or near HDR brachytherapy target.

    o Prior local excision is not an exclusion criterion.

  4. Uncontrolled intercurrent severe illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written .
  5. \<3 years per provider discretion.
  6. Concurrent administration of any cytotoxic chemotherapy, immunotherapy, or other any targeted oncologic agent that would impact rectal cancer is not allowed during study protocol.
  7. If rectal cancer has been treated outside of standard total therapy per NCCN guidelines, patients are ineligible for the trial. This includes if patients received external beam chemoradiation dose with prescription >56 Gy or short-course radiation to rectal mucosa prescription >30 Gy.
  8. Pregnant women.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    HDR Rectal Brachytherapy Boost

    The intervention consists of a boost using Iridium-192 delivered via an intracavitary applicator in three weekly fractions totaling 21 Gy. The goal is to improve organ preservation rates and avoid surgical resection (APR or low LAR). Treatment planning includes MRI, endoscopic clip placement, and CT simulation prior to each fraction.

    Radiation: High Rare Dose Rectal Brachytherapy Boost

Interventions

  • RadiationHigh Rare Dose Rectal Brachytherapy Boost

    HDR rectal brachytherapy boost using Iridium-192 delivered via an intracavitary applicator in three weekly fractions (total dose: 21 Gy) for patients with low-lying residual rectal adenocarcinoma following total neoadjuvant therapy.

06

What researchers measure

Primary outcomes

  1. Organ preservation (no surgical requirement) of the rectum associated with complete clinical response

    As evaluated by standard of care sigmoidoscopy and MRI

    Time frame: 2 years following study treatment

Secondary outcomes

  1. Locoregional recurrence free survival

    As defined by CT and MRI pelvis

    Time frame: 2 years following study treatment

  2. Distant metastatic free survivial

    As assessed by CT c/a/p

    Time frame: 2 years following study treatment

  3. Overall survival

    Overall survival

    Time frame: 2 years following study treatment

  4. Bowel function

    As assessed by LARS (low anterior resection syndrome) questionnaire

    Time frame: 2 years following study treatment

07

Study locations

1 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.

Of 228 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 48 months is close to that.

Counting every sponsor, half of 242 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 18, 2025
StartEst.
Nov 2026
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2031
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07292298
Collaborators
Cancer League of Colorado
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Nov 2026 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Nov 2031 (estimated)
Last update
Sep 2, 2026

Study contacts

Radiation Therapy Group
Contact
RTClinicalResearch@olucdenver.onmicrosoft.com
303-724-8822
David Binder
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion